Ocular Therapeutix has successfully completed enrollment in the phase 3 SOL-R clinical trial for wet age-related macular degeneration (AMD), marking a significant milestone in retinal TKI research. This achievement, achieved within a year of conceptualization, highlights the company’s dedication to advancing innovative treatments for patients with wet AMD. The SOL-R trial, the largest of its kind to date, along with the complementary SOL-1 trial, are aligned with FDA requirements and hold the potential to establish a strong clinical foundation. The goal is to support an AXPAXLI label with a unique superiority claim and a groundbreaking dosing schedule of 6 to 12 months. The focus now shifts to meticulous trial execution, with positive feedback on participant retention and adherence to protocol in both SOL-1 and SOL-R trials.The completion of enrollment in the SOL-R trial not only signifies progress in the treatment of wet AMD but also sets the stage for potential future advancements in the field. The disciplined approach to trial execution and the high level of participant engagement bode well for the success of these trials. With the possibility of achieving an AXPAXLI label with superior dosing regimens, the outcomes of these trials could significantly impact the management of wet AMD. As the trials progress, further insights into the efficacy and safety of the investigational treatment can be expected, paving the way for potential regulatory approvals and advancements in patient care. The commitment to innovation and patient-centric research demonstrated by Ocular Therapeutix is a promising sign for the future of retinal therapeutics.
Read more from ophthalmologytimes.com
